Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio
Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio
05/30/24, 8:07 PM
Location
wilmingtonsan diegoIndustry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
therapeutics
biotechnology
Incyte has successfully completed the acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company that focuses on novel small molecule therapeutics. This acquisition strengthens Incyte's commitment to creating innovative solutions for severe inflammatory diseases and bolsters its Inflammation and Autoimmunity portfolio, adding EP262 and EP547 to its portfolio.
Company Info
Location
Wilmington, Delaware, United States
Company info
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.